FDA
-
-
-
-
-
-
-
Inozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights
-
-
-
-
-
-
-
Inozyme Pharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights
-
-
-
-
-
-
-
Inozyme Pharma (INZY) Reports Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701
-
-
-
-
-
-
-
Inozyme Pharma Secures Flexible Debt Facility for up to $70 Million with K2 HealthVentures
-
-
-
-
-
-
-
Inozyme Pharma Inc. (INZY) Doses First Patients in Phase 1/2 Clinical Trials in ABCC6 Deficiency and ENPP1 Deficiency
-
-
-
-
-
-
-
Inozyme Pharma Strengthens Management Team with Two Executive Appointments
-
-
-
-
-
-
-
Inozyme Pharma Receives Orphan Drug Designation for INZ-701 from the European Medicines Agency for the Treatment of ABCC6 Deficiency
-
251,395 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All